Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
Artemether-Lumefantrine vs ACULAR PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Artemether is rapidly converted to dihydroartemisinin, which produces free radicals that damage parasite proteins and membranes. Lumefantrine inhibits heme detoxification in the parasite food vacuole.
Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. It produces anti-inflammatory and analgesic effects.
Treatment of uncomplicated malaria due to Plasmodium falciparum,Treatment of chloroquine-resistant malaria
FDA-approved: Treatment of ocular inflammation and pain following cataract surgery and corneal refractive surgery.,Off-label: Relief of seasonal allergic conjunctivitis symptoms, management of cystoid macular edema, and treatment of postoperative inflammation in other ocular procedures.
Oral, 4 tablets (each containing 20 mg artemether and 120 mg lumefantrine) at 0, 8, 24, 36, 48, and 60 hours (total 6 doses). For patients ≥35 kg, alternatively 4 tablets at 0, 8, 24, 36, 48, and 60 hours.
1 drop into affected eye(s) four times daily (every 6 hours). Instill into conjunctival sac. Shake well before use.
Artemether: terminal elimination half-life approximately 1–2 hours. Dihydroartemisinin: approximately 1–2 hours. Lumefantrine: terminal elimination half-life 4–5 days (range 2–6 days) in patients with uncomplicated malaria; prolonged half-life contributes to post-treatment prophylaxis but may lead to accumulation with repeated dosing.
Terminal elimination half-life is approximately 5-6 hours in adults, but can be prolonged in elderly patients (up to 8-9 hours) and in patients with renal impairment (up to 13-19 hours).
Artemether is metabolized by CYP3A4 to dihydroartemisinin. Lumefantrine is metabolized by CYP3A4.
Ketorolac undergoes hepatic metabolism via hydroxylation and conjugation (glucuronidation) to inactive metabolites. It is primarily metabolized by CYP2D6 and CYP3A4 isoenzymes, with renal excretion of metabolites and unchanged drug.
Primarily fecal (biliary) elimination of unchanged drug and metabolites; renal excretion is negligible (<1% for artemether and <0.1% for lumefantrine). Artemether is extensively metabolized by CYP3A4/5 to dihydroartemisinin, which is further glucuronidated and excreted in bile. Lumefantrine is metabolized by CYP3A4 to desbutyl-lumefantrine; both parent and metabolite are eliminated via feces.
Primarily renal excretion of metabolites and unchanged drug; approximately 80% of a dose is excreted in urine as ketorolac and its hydroxy metabolites, with about 6% excreted in feces.
Artemether: 95% bound to plasma proteins (primarily albumin and α1-acid glycoprotein). Dihydroartemisinin: 93% bound. Lumefantrine: >99% bound to high-density lipoproteins (HDL) and, to a lesser extent, to albumin and α1-acid glycoprotein.
99% bound to plasma proteins, primarily albumin.
Artemether: Vd approximately 2–5 L/kg, indicating extensive tissue distribution. Dihydroartemisinin: Vd 0.5–1.5 L/kg. Lumefantrine: Vd extremely large, ranging from 10–30 L/kg (reported up to 31 L/kg), reflecting extensive tissue binding and accumulation in erythrocytes and organs (liver, lung, kidney).
0.15-0.25 L/kg after oral administration; for ophthalmic use, systemic absorption is minimal, so Vd is not clinically meaningful.
Oral bioavailability: Artemether is 30–40% due to extensive first-pass metabolism by CYP3A4/5 to dihydroartemisinin, which has 80% oral bioavailability. Lumefantrine has highly variable and food-dependent bioavailability; absorption increases 2–16 fold when taken with a high-fat meal. Bioavailability is approximately 5–10% in the fasted state and up to 85% when administered with fat-containing food. The combination is formulated to enhance lumefantrine absorption with a fixed ratio of artemether:lumefantrine 1:6.
Ophthalmic administration: Systemic bioavailability is approximately 0.5-1% after ocular instillation due to low corneal penetration and rapid clearance; oral bioavailability is 100%.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min); use with caution.
No dosage adjustment required for renal impairment. Drug is minimally absorbed systemically.
No dose adjustment for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); avoid use.
No dosage adjustment required for hepatic impairment. Drug is minimally absorbed systemically.
Weight-based dosing: 5-<15 kg: 1 tablet per dose; 15-<25 kg: 2 tablets per dose; 25-<35 kg: 3 tablets per dose; ≥35 kg: 4 tablets per dose. Administer at 0, 8, 24, 36, 48, and 60 hours. Crush tablets if needed for children <5 kg.
Children ≥3 years: 1 drop into affected eye(s) four times daily. Safety and efficacy in children <3 years not established.
No specific dose adjustment required. Monitor for QT prolongation and electrolyte disturbances due to potential age-related decline in cardiac conduction.
No specific dosage adjustment required. Use same dose as adults; monitor for tolerability.
None
NSAIDs may increase the risk of serious cardiovascular events (e.g., myocardial infarction, stroke) and gastrointestinal events (e.g., bleeding, ulceration, perforation). However, due to low systemic absorption with ophthalmic use, this boxed warning is less clinically relevant but still applies.
QT interval prolongation,Arrhythmias,Recrudescence of infection,Hypersensitivity reactions,Use in hepatic impairment
Use with caution in patients with compromised ocular surface, history of herpes simplex keratitis, bleeding tendencies, or those on anticoagulants. Prolonged use may delay wound healing. Monitor for signs of corneal epithelial breakdown or infection.
Hypersensitivity to artemether or lumefantrine,Severe malaria,Pregnancy (first trimester) unless no other option
Hypersensitivity to ketorolac or any component of the formulation; patients with active ocular infection or advanced dry eye; history of asthma, urticaria, or allergic-type reactions to aspirin or other NSAIDs.
High-fat meal increases absorption; grapefruit juice may increase lumefantrine levels; avoid concurrent use.
No known food interactions. No dietary restrictions required.
FDA Pregnancy Category C. Artemether-lumefantrine is not recommended in the first trimester unless no alternative; animal studies show embryotoxicity at high doses. Second and third trimester: limited human data but appears safe; no increased risk of congenital malformations reported. Use only if benefit outweighs risk.
FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, ketorolac tromethamine (active ingredient) was not teratogenic in rats or rabbits at doses up to 1.5-3 times the human exposure. However, because NSAIDs can cause premature closure of the ductus arteriosus and oligohydramnios in the third trimester, use is contraindicated after 30 weeks gestation. In first and second trimesters, use only if potential benefit justifies potential fetal risk.
Both artemether and lumefantrine are excreted in breast milk in low amounts. M/P ratio: artemether ~0.3, lumefantrine ~0.5. Considered compatible with breastfeeding; no adverse effects observed in infants. Use caution if infant has G6PD deficiency due to theoretical risk of hemolysis.
Ketorolac is excreted in human milk following oral administration. After a single intramuscular dose of 10 mg, the milk-to-plasma (M/P) ratio was 0.037. Low levels are expected in breastmilk; however, due to potential adverse effects of NSAIDs on neonates, caution is advised. Use is generally avoided in nursing mothers, especially with premature infants or those with thrombocytopenia or renal impairment.
No dose adjustment required for uncomplicated malaria in second and third trimester. First trimester: avoid unless no alternative; use same weight-based dosing. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered metabolism) do not mandate dose changes; standard 6-dose regimen over 3 days is recommended.
No specific pharmacokinetic studies in pregnancy. Dosing should be at the lowest effective dose for the shortest duration. Avoid use after 30 weeks gestation. No adjustment for first or second trimester unless renal function changes.
Monitor ECG for QTc prolongation; administer with fatty food to enhance absorption; avoid in patients with severe hepatic impairment; pregnancy category C; caution with CYP3A4 inhibitors or inducers.
ACULAR (ketorolac tromethamine ophthalmic solution) is an NSAID for ocular use. Preservative-free formulation is indicated for single-use to avoid corneal toxicity. Apply with caution in patients with bleeding disorders or those on anticoagulants due to risk of ocular bleeding. Prolonged use may delay corneal healing. Monitor for signs of keratitis or conjunctival hyperemia.
Take with a high-fat meal or whole milk to improve absorption.,Complete the full 3-day course even if symptoms improve.,Seek medical attention for signs of severe malaria (e.g., altered consciousness, difficulty breathing).,Avoid grapefruit juice during treatment.,Use effective contraception if of childbearing potential.
Use exactly as prescribed; do not touch the dropper tip to any surface to avoid contamination.,Each single-use vial is for one dose only; discard after use to prevent infection.,Remove contact lenses before instillation and wait 10 minutes before reinserting.,Do not drive or operate machinery if vision is blurry after application.,Report eye pain, increased redness, or vision changes to your doctor immediately.
"Anagrelide, a phosphodiesterase 3 (PDE3) inhibitor used for thrombocythemia, and artemether, an antimalarial artemisinin derivative, both prolong the QT interval by inhibiting cardiac potassium channels (specifically IKr). Concurrent use may result in additive QTc prolongation, increasing the risk of Torsade de Pointes and other ventricular arrhythmias. This risk is particularly relevant in patients with electrolyte imbalances, bradycardia, or pre-existing cardiac disease."
"Acepromazine, a phenothiazine antipsychotic/antiemetic, inhibits cytochrome P450 3A4 (CYP3A4), the primary enzyme responsible for metabolizing the antimalarial artemether. Concomitant administration can lead to significantly reduced clearance of artemether, elevating its plasma concentrations. This may increase the risk of dose-dependent toxicities, including neurotoxicity (e.g., ataxia, seizures) and cardiotoxicity (e.g., QT prolongation)."
"Concomitant administration of thioridazine, a potent CYP2D6 inhibitor, with artemether, a substrate of CYP2D6, can significantly increase the serum concentration of artemether. This elevation may potentiate the antimalarial effect but also heightens the risk of artemether-related adverse effects such as QT prolongation and neurotoxicity. Clinically, this interaction warrants caution due to potential cardiotoxicity and altered drug exposure."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about Artemether-Lumefantrine vs ACULAR PRESERVATIVE FREE, answered by our medical review team.
Artemether-Lumefantrine is a Antimalarial that works by Artemether is rapidly converted to dihydroartemisinin, which produces free radicals that damage parasite proteins and membranes. Lumefantrine inhibits heme detoxification in the parasite food vacuole.. ACULAR PRESERVATIVE FREE is a NSAID Ophthalmic that works by Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. It produces anti-inflammatory and analgesic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between Artemether-Lumefantrine and ACULAR PRESERVATIVE FREE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of Artemether-Lumefantrine is: Oral, 4 tablets (each containing 20 mg artemether and 120 mg lumefantrine) at 0, 8, 24, 36, 48, and 60 hours (total 6 doses). For patients ≥35 kg, alternatively 4 tablets at 0, 8, 24, 36, 48, and 60 hours.. The standard adult dose of ACULAR PRESERVATIVE FREE is: 1 drop into affected eye(s) four times daily (every 6 hours). Instill into conjunctival sac. Shake well before use.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between Artemether-Lumefantrine and ACULAR PRESERVATIVE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. Artemether-Lumefantrine is classified as Category C. FDA Pregnancy Category C. Artemether-lumefantrine is not recommended in the first trimester unless no alternative; animal studies show embryotoxicity at high doses. Second and thir. ACULAR PRESERVATIVE FREE is classified as Category C. FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, ketorolac tromethamine (active ingredient) was not teratogenic in rats or rabbits at doses up to. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.